Stoke Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Stoke Therapeutics, Inc. (STOK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 868.99 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-03-16
- Stoke Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 868.99K shares, a 123.47% increase from fiscal 2024.
- Stoke Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 388.87K shares, a 73.17% decline from fiscal 2023.
- Stoke Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.45M shares, a 469.53% increase from fiscal 2022.
- Stoke Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 254.45K shares, a 506.22% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|
| 2025-12-31 | 868.99K shares 10-K · filed 2026-03-16 |
| 2024-12-31 | 388.87K shares 10-K · filed 2025-03-18 |
| 2023-12-31 | 1.45M shares 10-K · filed 2024-03-25 |
| 2022-12-31 | 254.45K shares 10-K · filed 2023-03-06 |
| 2021-12-31 | 41.97K shares 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |